Summary of findings: bevacizumab vs ranibizumab
No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
- Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes onlyRR 0.96 [0.9, 1.04]1 study · 548 participantsModerate